The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo

Despite recent advances in the development of novel therapies against castration-resistant prostate cancer, the advanced form of the disease remains a major treatment challenge. Aberrant sphingolipid signaling through sphingosine kinases and their product, sphingosine-1-phosphate, can promote proliferation, drug resistance, angiogenesis, and inflammation. The sphingosine kinase 2 inhibitor ABC294640 is undergoing clinical testing in cancer patients, and in this study we investigated the effects this first-in-class inhibitor in castration-resistant prostate cancer. In vitro, ABC294640 decreased prostate cancer cell viability as well as the expression of c-Myc and the androgen receptor, while lysosomal acidification increased. ABC294640 also induced a greater than 3-fold increase in dihydroceramides that inversely correlated with inhibition of dihydroceramide desaturase (DEGS) activity. Expression of sphingosine kinase 2 was dispensable for the ABC294640-mediated increase in dihydroceramides. In vivo, ABC294640 diminished the growth rate of TRAMP-C2 xenografts in syngeneic hosts and elevated dihydroceramides within tumors as visualized by MALDI imaging mass spectroscopy. The plasma of ABC294640-treated mice contained significantly higher levels of C16- and C24:1-ceramides (but not dihydro-C16-ceramide) compared with vehicle-treated mice. In summary, our results suggest that ABC294640 may reduce the proliferative capacity of castration-resistant prostate cancer cells through inhibition of both sphingosine kinase 2 and dihydroceramide desaturase, thereby providing a foundation for future exploration of this small-molecule inhibitor for the treatment of advanced disease. Mol Cancer Ther; 14(12); 2744–52. ©2015 AACR.

[1]  Charles D Smith,et al.  Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts , 2011, Cancer biology & therapy.

[2]  A. Bielawska,et al.  Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. , 2013, The Journal of clinical investigation.

[3]  Jayne M. Silver,et al.  Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model , 2015, Molecular Cancer Therapeutics.

[4]  S. Pyne,et al.  The sphingosine kinase inhibitor 2‐(p‐hyroxyanilino)‐4‐(p‐chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress‐dependent mechanism , 2013, British journal of pharmacology.

[5]  L. Obeid,et al.  Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors. , 2013, Biochimica et biophysica acta.

[6]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[7]  X. Rao,et al.  Gamma‐tocotrienol induces apoptosis and autophagy in prostate cancer cells by increasing intracellular dihydrosphingosine and dihydroceramide , 2012, International journal of cancer.

[8]  S. Rauser,et al.  Normalization in MALDI-TOF imaging datasets of proteins: practical considerations , 2011, Analytical and bioanalytical chemistry.

[9]  Jin H. Song,et al.  Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. , 2014, Blood.

[10]  A. Bielawska,et al.  Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). , 2010, Advances in experimental medicine and biology.

[11]  A. Kopp-Schneider,et al.  A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy , 2014, Cell Death and Disease.

[12]  J. Aragon-Ching,et al.  Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies , 2014, Therapeutics and clinical risk management.

[13]  Y. Zhuang,et al.  Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn’s disease , 2010, Inflammopharmacology.

[14]  B. Foster,et al.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.

[15]  Michael D. Henry,et al.  Assessing Tumor Growth and Distribution in a Model of Prostate Cancer Metastasis using Bioluminescence Imaging , 2006, Clinical & Experimental Metastasis.

[16]  Y. Hannun,et al.  Identification of Dihydroceramide Desaturase as a Direct in Vitro Target for Fenretinide* , 2011, The Journal of Biological Chemistry.

[17]  J. Casas,et al.  Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II[S] , 2014, Journal of Lipid Research.

[18]  T. Tirodkar,et al.  Sphingolipids in apoptosis. , 2012, Experimental oncology.

[19]  L. Del Valle,et al.  Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-Associated Primary Effusion Lymphoma , 2013, Molecular Cancer Therapeutics.

[20]  C. Wallington-Beddoe,et al.  Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression. , 2014, Cancer research.

[21]  D. Beach,et al.  Myc confers androgen-independent prostate cancer cell growth. , 2003, The Journal of clinical investigation.

[22]  C. Xie,et al.  ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer , 2015, Cancer biology & therapy.

[23]  J. Stebbing,et al.  Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer , 2011, Nature Reviews Urology.

[24]  Y. Peterson,et al.  Characterization of Isoenzyme-Selective Inhibitors of Human Sphingosine Kinases , 2012, PloS one.

[25]  S. Pitson,et al.  Roles, regulation and inhibitors of sphingosine kinase 2 , 2013, The FEBS journal.

[26]  P. Lu,et al.  In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL , 2006, Cancer Gene Therapy.

[27]  T. Mosher,et al.  Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase , 2011, Inflammopharmacology.

[28]  Daniel Bottomly,et al.  Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation , 2013, PloS one.

[29]  D. Tindall,et al.  Ligand-independent Androgen Receptor Activity Is Activation Function-2-independent and Resistant to Antiandrogens in Androgen Refractory Prostate Cancer Cells* , 2006, Journal of Biological Chemistry.

[30]  Deepak Poudyal,et al.  Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. , 2010, Carcinogenesis.

[31]  L. Chan,et al.  Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640. , 2013, Anticancer research.

[32]  L. Obeid,et al.  Regulation of the sphingosine kinase/sphingosine 1-phosphate pathway. , 2013, Handbook of experimental pharmacology.

[33]  J. Nofer,et al.  Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R−/−) mice , 2012, Thrombosis and Haemostasis.

[34]  A. Bielawska,et al.  Involvement of Dihydroceramide Desaturase in Cell Cycle Progression in Human Neuroblastoma Cells* , 2007, Journal of Biological Chemistry.

[35]  L. Rhodes,et al.  Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. , 2010, Endocrinology.

[36]  M. Burow,et al.  Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival , 2014, Pharmacological reports : PR.

[37]  Charles D Smith,et al.  Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion. , 2012, Journal of hepatology.

[38]  Charles D Smith,et al.  A Novel Sphingosine Kinase Inhibitor Induces Autophagy in Tumor Cells , 2010, Journal of Pharmacology and Experimental Therapeutics.

[39]  M. Burow,et al.  Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer , 2012, Experimental biology and medicine.

[40]  Steven Elliott,et al.  Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2 , 2011, Cancer biology & therapy.

[41]  Benjamin A. Neely,et al.  MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma , 2014, Proteomics.

[42]  T. Visakorpi,et al.  Genetic alterations in hormone-refractory recurrent prostate carcinomas. , 1998, The American journal of pathology.

[43]  Charles D Smith,et al.  Inhibition of Sphingosine Kinase-2 Suppresses Inflammation and Attenuates Graft Injury after Liver Transplantation in Rats , 2012, PloS one.

[44]  Y. Zhuang,et al.  Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2 , 2010, Journal of Pharmacology and Experimental Therapeutics.

[45]  Y. Zhuang,et al.  Combined anticancer effects of sphingosine kinase inhibitors and sorafenib , 2011, Investigational New Drugs.